Margaret G. McGlynn has served as a member of our Board since October 2009. She retired from Merck after 26 years including roles as President of Global Vaccines and Infectious Disease and President, U.S. Hospital and Specialty Products. She also served in a variety of executive leadership roles in global and U.S. marketing, sales and managed care. Following her retirement from Merck, Ms. McGlynn served as CEO and President of The International AIDS Vaccine Initiative. Currently, Ms. McGlynn serves as a member of the Board of Directors of Novavax, Inc. She also serves on the Board of Buffalo BioNet Advisory Group (private) and the Board of the Advisory Committee, UB School of Pharmacy (private). Previously, she served on the Boards of Air Products and Chemicals, Inc., Orphan Technologies, and Vertex Pharmaceuticals, Inc. She is also Chair of the Board of HCU Network America, a non‑profit which provides advocacy and support research for patients affected by the rare disease homocystinuria. Ms. McGlynn holds a B.S. in Pharmacy and a MBA in Marketing from the State University of New York at Buffalo.
Ms. McGlynn serves as chair of the Compensation and Leadership Development Committee and as member of the Nominating and Corporate Governance Committee.